** Shares of ophthalmic therapies developer Cloudbreak Pharma Inc 
2592 jump 13.5% to HK$8.24, highest level since July 3, and on course for sixth straight session of gains
** Stock on track to conclude the month up 71.1%, the hugegest monthly gain since debut in Hong Kong on July 3
** Company declares Japan Patent Office and European Patent Office have granted patents to its core product CBT-009 for treatment of juvenile myopia in children and adolescents aged 5 to 19 years
** Success of the patent applications will enhance CBT-009’s global reach and facilitate its collaboration with pharma corporations in establishing licensing arrangements for the manufacture, distribution of CBT-009 in Japan and Europe
** Since their July debut, Cloudbreak shares down 18.8% so far from the offer price HK$10.10
** YTD, Hong Kong’s healthcare index (.HSCIH) up 73.8%
